George Health Enterprises and its subsidiary George Medicines have raised a combined $35m in funding from investors including Bupa Australia to drive pipeline development and commercialisation.
George Health Enterprises, the UK-based commercial arm of George Institute for Global Health operating an integrated healthcare business, and its drug development subsidiary George Medicines secured £27m ($35m) in combined funding yesterday.
The capital is split into $22m for George Health, co-led by health insurer Bupa Australia and private equity fund Federation Asset Management, and $13m for George Medicines, supplied by the Medical Research Commercialisation Fund (MRCF).
MRCF, backed by the government of Australia and managed by Brandon…
